Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia

Srijoy Mahapatra, Damien J. Lapar, Castigliano Bhamidipati, George McDaniel, Sandeep Kamath, T. Jared Bunch, Gorav Ailawadi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: We sought to determine the incidence, predictors, and consequences of new-onset atrial fibrillation (AF) following epicardial ventricular tachycardia (VT) ablation. Methods and results: A total of 41 patients with no prior history of AF underwent epicardial VT ablation via a percutaneous subxiphoid approach. All patients were monitored continuously for 3 days following ablation and then via implantable cardiac defibrillator (ICD) or Holter monitoring. Mean age was 70.0 ± 11.3 years and mean ejection fraction was 30.3 ± 16.6%. In seven (17%) patients, the right ventricle (RV) was punctured during access with subsequent needle withdrawal without requiring surgical repair. Thirty patients (73%) were treated with amiodarone following ablation. Post-ablation, eight (19.5%) patients had documented new-onset AF within 7 days. All AF patients had clinical symptoms of pericarditis. One patient with AF was maintained on amiodarone post-procedure. Complications of AF included three patients who received inappropriate ICD shocks and one patient who developed a large, left atrial appendage clot. Acutely, all patients responded to short-term medical therapy or electrical cardioversion. At 18.0 ± 9.0 months of follow-up, no patient had recurrence of AF, and all were off antiarrhythmic drugs. One patient had typical atrial flutter requiring catheter ablation. Risk factors for AF included lack of amiodarone immediately after ablation (12.5 vs. 87.9%, P< 0.001), RV puncture (50.0 vs. 9.1%, P = 0.02), and epicardial ablation time >10 min (62.5 vs. 3.0%, P< 0.001). Conclusions: Atrial fibrillation after epicardial ablation is common and can lead to ICD shocks and atrial thrombus formation. Short-term antiarrhythmic drug therapy and ICD reprogramming should be considered after epicardial VT ablation. Published on behalf of the European Society of Cardiology. All rights reserved.

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalEuropace
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Ventricular Tachycardia
Atrial Fibrillation
Incidence
Implantable Defibrillators
Amiodarone
Anti-Arrhythmia Agents
Shock
Atrial Appendage
Electric Countershock
Ambulatory Electrocardiography
Atrial Flutter
Pericarditis
Catheter Ablation
Patient Rights
Heart Ventricles
Needles
Thrombosis
Recurrence
Drug Therapy

Keywords

  • Ablation
  • Atrial fibrillation
  • Epicardial
  • Implantable cardiac defibrillator shocks
  • Ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia. / Mahapatra, Srijoy; Lapar, Damien J.; Bhamidipati, Castigliano; McDaniel, George; Kamath, Sandeep; Bunch, T. Jared; Ailawadi, Gorav.

In: Europace, Vol. 13, No. 4, 01.04.2011, p. 548-554.

Research output: Contribution to journalArticle

Mahapatra, Srijoy ; Lapar, Damien J. ; Bhamidipati, Castigliano ; McDaniel, George ; Kamath, Sandeep ; Bunch, T. Jared ; Ailawadi, Gorav. / Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia. In: Europace. 2011 ; Vol. 13, No. 4. pp. 548-554.
@article{542779bf26da4cfd889f000c38f7b10a,
title = "Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia",
abstract = "Introduction: We sought to determine the incidence, predictors, and consequences of new-onset atrial fibrillation (AF) following epicardial ventricular tachycardia (VT) ablation. Methods and results: A total of 41 patients with no prior history of AF underwent epicardial VT ablation via a percutaneous subxiphoid approach. All patients were monitored continuously for 3 days following ablation and then via implantable cardiac defibrillator (ICD) or Holter monitoring. Mean age was 70.0 ± 11.3 years and mean ejection fraction was 30.3 ± 16.6{\%}. In seven (17{\%}) patients, the right ventricle (RV) was punctured during access with subsequent needle withdrawal without requiring surgical repair. Thirty patients (73{\%}) were treated with amiodarone following ablation. Post-ablation, eight (19.5{\%}) patients had documented new-onset AF within 7 days. All AF patients had clinical symptoms of pericarditis. One patient with AF was maintained on amiodarone post-procedure. Complications of AF included three patients who received inappropriate ICD shocks and one patient who developed a large, left atrial appendage clot. Acutely, all patients responded to short-term medical therapy or electrical cardioversion. At 18.0 ± 9.0 months of follow-up, no patient had recurrence of AF, and all were off antiarrhythmic drugs. One patient had typical atrial flutter requiring catheter ablation. Risk factors for AF included lack of amiodarone immediately after ablation (12.5 vs. 87.9{\%}, P< 0.001), RV puncture (50.0 vs. 9.1{\%}, P = 0.02), and epicardial ablation time >10 min (62.5 vs. 3.0{\%}, P< 0.001). Conclusions: Atrial fibrillation after epicardial ablation is common and can lead to ICD shocks and atrial thrombus formation. Short-term antiarrhythmic drug therapy and ICD reprogramming should be considered after epicardial VT ablation. Published on behalf of the European Society of Cardiology. All rights reserved.",
keywords = "Ablation, Atrial fibrillation, Epicardial, Implantable cardiac defibrillator shocks, Ventricular tachycardia",
author = "Srijoy Mahapatra and Lapar, {Damien J.} and Castigliano Bhamidipati and George McDaniel and Sandeep Kamath and Bunch, {T. Jared} and Gorav Ailawadi",
year = "2011",
month = "4",
day = "1",
doi = "10.1093/europace/eur017",
language = "English (US)",
volume = "13",
pages = "548--554",
journal = "Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia

AU - Mahapatra, Srijoy

AU - Lapar, Damien J.

AU - Bhamidipati, Castigliano

AU - McDaniel, George

AU - Kamath, Sandeep

AU - Bunch, T. Jared

AU - Ailawadi, Gorav

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Introduction: We sought to determine the incidence, predictors, and consequences of new-onset atrial fibrillation (AF) following epicardial ventricular tachycardia (VT) ablation. Methods and results: A total of 41 patients with no prior history of AF underwent epicardial VT ablation via a percutaneous subxiphoid approach. All patients were monitored continuously for 3 days following ablation and then via implantable cardiac defibrillator (ICD) or Holter monitoring. Mean age was 70.0 ± 11.3 years and mean ejection fraction was 30.3 ± 16.6%. In seven (17%) patients, the right ventricle (RV) was punctured during access with subsequent needle withdrawal without requiring surgical repair. Thirty patients (73%) were treated with amiodarone following ablation. Post-ablation, eight (19.5%) patients had documented new-onset AF within 7 days. All AF patients had clinical symptoms of pericarditis. One patient with AF was maintained on amiodarone post-procedure. Complications of AF included three patients who received inappropriate ICD shocks and one patient who developed a large, left atrial appendage clot. Acutely, all patients responded to short-term medical therapy or electrical cardioversion. At 18.0 ± 9.0 months of follow-up, no patient had recurrence of AF, and all were off antiarrhythmic drugs. One patient had typical atrial flutter requiring catheter ablation. Risk factors for AF included lack of amiodarone immediately after ablation (12.5 vs. 87.9%, P< 0.001), RV puncture (50.0 vs. 9.1%, P = 0.02), and epicardial ablation time >10 min (62.5 vs. 3.0%, P< 0.001). Conclusions: Atrial fibrillation after epicardial ablation is common and can lead to ICD shocks and atrial thrombus formation. Short-term antiarrhythmic drug therapy and ICD reprogramming should be considered after epicardial VT ablation. Published on behalf of the European Society of Cardiology. All rights reserved.

AB - Introduction: We sought to determine the incidence, predictors, and consequences of new-onset atrial fibrillation (AF) following epicardial ventricular tachycardia (VT) ablation. Methods and results: A total of 41 patients with no prior history of AF underwent epicardial VT ablation via a percutaneous subxiphoid approach. All patients were monitored continuously for 3 days following ablation and then via implantable cardiac defibrillator (ICD) or Holter monitoring. Mean age was 70.0 ± 11.3 years and mean ejection fraction was 30.3 ± 16.6%. In seven (17%) patients, the right ventricle (RV) was punctured during access with subsequent needle withdrawal without requiring surgical repair. Thirty patients (73%) were treated with amiodarone following ablation. Post-ablation, eight (19.5%) patients had documented new-onset AF within 7 days. All AF patients had clinical symptoms of pericarditis. One patient with AF was maintained on amiodarone post-procedure. Complications of AF included three patients who received inappropriate ICD shocks and one patient who developed a large, left atrial appendage clot. Acutely, all patients responded to short-term medical therapy or electrical cardioversion. At 18.0 ± 9.0 months of follow-up, no patient had recurrence of AF, and all were off antiarrhythmic drugs. One patient had typical atrial flutter requiring catheter ablation. Risk factors for AF included lack of amiodarone immediately after ablation (12.5 vs. 87.9%, P< 0.001), RV puncture (50.0 vs. 9.1%, P = 0.02), and epicardial ablation time >10 min (62.5 vs. 3.0%, P< 0.001). Conclusions: Atrial fibrillation after epicardial ablation is common and can lead to ICD shocks and atrial thrombus formation. Short-term antiarrhythmic drug therapy and ICD reprogramming should be considered after epicardial VT ablation. Published on behalf of the European Society of Cardiology. All rights reserved.

KW - Ablation

KW - Atrial fibrillation

KW - Epicardial

KW - Implantable cardiac defibrillator shocks

KW - Ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=79953775338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953775338&partnerID=8YFLogxK

U2 - 10.1093/europace/eur017

DO - 10.1093/europace/eur017

M3 - Article

C2 - 21296778

AN - SCOPUS:79953775338

VL - 13

SP - 548

EP - 554

JO - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

JF - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

SN - 1099-5129

IS - 4

ER -